Waters Corporation WAT
433.54
3.24
0.75%
as of 25 Sep
- Market cap
- $42.3B
- P/E
- 108×
Follow WAT
Indexes
indicate stock being part of an index,
Insider Buys
alert about insiders buying in the last 12 month
Waters Corporation (WAT) Revenue
Waters Corporation's revenue for fiscal 2025 was $3.2B, up 6.99% from $3.0B in fiscal 2024. Over the twelve months to 30 June 2026 it was $4.6B. Over the past ten years it has ranged from $2.0B (fiscal 2015) to $3.2B (fiscal 2025) — the current reading is the highest in ten years. Waters Corporation ranks 8th of 50 Diagnostics & Research companies by revenue.
Revenue, annual
Annual
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $3.2B | 6.99% |
| FY2024 | $3.0B | 0.07% |
| FY2023 | $3.0B | (0.52%) |
| FY2022 | $3.0B | 6.68% |
| FY2021 | $2.8B | 17.78% |
| FY2020 | $2.4B | (1.71%) |
| FY2019 | $2.4B | (0.55%) |
| FY2018 | $2.4B | 4.80% |
| FY2017 | $2.3B | 6.54% |
| FY2016 | $2.2B | 6.12% |
Quarterly
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $1.6B | 29.83% |
| Mar 2026 | $1.3B | 35.89% |
| Dec 2025 | $932.4M | 16.57% |
| Sep 2025 | $799.9M | 3.75% |
| 42 more quarters | Free account |
Against its own ten years
Low $2.0B
High $3.2B
Ten-year median
$2.4B
Current reading's percentile
100
Revenue against peers
| Company | Revenue |
|---|---|
| IQV IQVIA Holdings Inc. compare | $17.0B |
| DGX Quest Diagnostics Incorporated compare | $11.6B |
| A Agilent Technologies, Inc. compare | $7.4B |
| WAT Waters Corporation | $4.6B |
| IDXX IDEXX Laboratories, Inc. compare | $4.6B |
| ILMN Illumina, Inc. compare | $4.5B |
| MTD Mettler-Toledo International, Inc. compare | $4.1B |
| NTRA Natera, Inc. compare | $2.7B |
| GH Guardant Health, Inc. compare | $1.2B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on WAT
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement